Leila Azari , Homa Hemati , Ronia Tavasolian , Sareh Shahdab , Stephanie M. Tomlinson , Margarita Bobonis Babilonia , Jeffrey Huang , Danielle B. Tometich , Kea Turner , Heather S.L. Jim , Amir Alishahi Tabriz
{"title":"氯胺酮治疗癌症患者抑郁症的有效性和安全性：系统综述","authors":"Leila Azari , Homa Hemati , Ronia Tavasolian , Sareh Shahdab , Stephanie M. Tomlinson , Margarita Bobonis Babilonia , Jeffrey Huang , Danielle B. Tometich , Kea Turner , Heather S.L. Jim , Amir Alishahi Tabriz","doi":"10.1016/j.ijchp.2023.100428","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Management of depression in the oncology population includes supportive psychotherapeutic interventions with or without psychotropic medication, which take time to demonstrate effectiveness. Fast-acting interventions, like ketamine, can provide a rapid antidepressant effect; however, there has been limited research on effects of ketamine among cancer patients. The objective of this review is to provide an overview of research on the efficacy and safety of ketamine on depression in patients with cancer.</p></div><div><h3>Methods</h3><p>We reviewed the published literature in MEDLINE® (via PubMed®), EMBASE, and Scopus from 1 January 1982 to 20 October 2022. We screened the retrieved abstracts against inclusion criteria and conducted a full‐text review of eligible studies. Following extraction of data from included studies, we used a framework analysis approach to summarize the evidence on using ketamine in patients with cancer.</p></div><div><h3>Results</h3><p>All 5 included studies were randomized clinical trials conducted in inpatient settings in China. In all included studies ketamine was administered intravenously. Three studies used only racemic ketamine, and two studies used both S-ketamine and racemic ketamine. All included studies reported ketamine a tolerable and effective drug to control depression symptoms.</p></div><div><h3>Conclusion</h3><p>Included studies showed administration of sub-anesthesia ketamine significantly improves postoperative depression among patients with cancer.</p></div>","PeriodicalId":47673,"journal":{"name":"International Journal of Clinical and Health Psychology","volume":"24 1","pages":"Article 100428"},"PeriodicalIF":5.3000,"publicationDate":"2023-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1697260023000649/pdfft?md5=7e35195763b03243e7ff32b64c9c5e8d&pid=1-s2.0-S1697260023000649-main.pdf","citationCount":"0","resultStr":"{\"title\":\"The efficacy and safety of ketamine for depression in patients with cancer: A systematic review\",\"authors\":\"Leila Azari , Homa Hemati , Ronia Tavasolian , Sareh Shahdab , Stephanie M. Tomlinson , Margarita Bobonis Babilonia , Jeffrey Huang , Danielle B. Tometich , Kea Turner , Heather S.L. Jim , Amir Alishahi Tabriz\",\"doi\":\"10.1016/j.ijchp.2023.100428\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Management of depression in the oncology population includes supportive psychotherapeutic interventions with or without psychotropic medication, which take time to demonstrate effectiveness. Fast-acting interventions, like ketamine, can provide a rapid antidepressant effect; however, there has been limited research on effects of ketamine among cancer patients. The objective of this review is to provide an overview of research on the efficacy and safety of ketamine on depression in patients with cancer.</p></div><div><h3>Methods</h3><p>We reviewed the published literature in MEDLINE® (via PubMed®), EMBASE, and Scopus from 1 January 1982 to 20 October 2022. We screened the retrieved abstracts against inclusion criteria and conducted a full‐text review of eligible studies. Following extraction of data from included studies, we used a framework analysis approach to summarize the evidence on using ketamine in patients with cancer.</p></div><div><h3>Results</h3><p>All 5 included studies were randomized clinical trials conducted in inpatient settings in China. In all included studies ketamine was administered intravenously. Three studies used only racemic ketamine, and two studies used both S-ketamine and racemic ketamine. All included studies reported ketamine a tolerable and effective drug to control depression symptoms.</p></div><div><h3>Conclusion</h3><p>Included studies showed administration of sub-anesthesia ketamine significantly improves postoperative depression among patients with cancer.</p></div>\",\"PeriodicalId\":47673,\"journal\":{\"name\":\"International Journal of Clinical and Health Psychology\",\"volume\":\"24 1\",\"pages\":\"Article 100428\"},\"PeriodicalIF\":5.3000,\"publicationDate\":\"2023-12-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S1697260023000649/pdfft?md5=7e35195763b03243e7ff32b64c9c5e8d&pid=1-s2.0-S1697260023000649-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Clinical and Health Psychology\",\"FirstCategoryId\":\"102\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1697260023000649\",\"RegionNum\":1,\"RegionCategory\":\"心理学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PSYCHOLOGY, CLINICAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical and Health Psychology","FirstCategoryId":"102","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1697260023000649","RegionNum":1,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHOLOGY, CLINICAL","Score":null,"Total":0}
The efficacy and safety of ketamine for depression in patients with cancer: A systematic review
Background
Management of depression in the oncology population includes supportive psychotherapeutic interventions with or without psychotropic medication, which take time to demonstrate effectiveness. Fast-acting interventions, like ketamine, can provide a rapid antidepressant effect; however, there has been limited research on effects of ketamine among cancer patients. The objective of this review is to provide an overview of research on the efficacy and safety of ketamine on depression in patients with cancer.
Methods
We reviewed the published literature in MEDLINE® (via PubMed®), EMBASE, and Scopus from 1 January 1982 to 20 October 2022. We screened the retrieved abstracts against inclusion criteria and conducted a full‐text review of eligible studies. Following extraction of data from included studies, we used a framework analysis approach to summarize the evidence on using ketamine in patients with cancer.
Results
All 5 included studies were randomized clinical trials conducted in inpatient settings in China. In all included studies ketamine was administered intravenously. Three studies used only racemic ketamine, and two studies used both S-ketamine and racemic ketamine. All included studies reported ketamine a tolerable and effective drug to control depression symptoms.
Conclusion
Included studies showed administration of sub-anesthesia ketamine significantly improves postoperative depression among patients with cancer.
期刊介绍：
The International Journal of Clinical and Health Psychology is dedicated to publishing manuscripts with a strong emphasis on both basic and applied research, encompassing experimental, clinical, and theoretical contributions that advance the fields of Clinical and Health Psychology. With a focus on four core domains—clinical psychology and psychotherapy, psychopathology, health psychology, and clinical neurosciences—the IJCHP seeks to provide a comprehensive platform for scholarly discourse and innovation. The journal accepts Original Articles (empirical studies) and Review Articles. Manuscripts submitted to IJCHP should be original and not previously published or under consideration elsewhere. All signing authors must unanimously agree on the submitted version of the manuscript. By submitting their work, authors agree to transfer their copyrights to the Journal for the duration of the editorial process.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
